No Data
JonesTrading Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $22
JMP Securities Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $17
Acrivon Therapeutics: Promising Innovations in WEE1/PKMYT1 Inhibition and AP3 Platform Drive Buy Rating
Acrivon Therapeutics to Present Data Demonstrating Deployment of Its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
No Data
No Data